SCHEMBL1767974

SCHEMBL1767974

CCCCC(C(=O)OCC)c1ccc(N)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.47
CYP1A2 P05177 3/20 0.47
CYP3A4 P08684 3/20 0.47
MAOA P21397 1/20 0.47
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46
PDE4D Q08499 1/20 0.46
ALDH1A1 P00352 2/20 0.46
HTT P42858 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MAPT P10636 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.40
MAPK1 P28482 1/20 0.40
CHRM2 P08172 1/20 0.40
HTR1A P08908 1/20 0.40
GAA P10253 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL12273789 0.98 LMNA (0.46) LMNACYP1A2CYP3A4MAOACYP2C9
SCHEMBL9090315 0.94 ALDH1A1 (0.49) LMNACYP1A2CYP3A4MAOACYP2C9
SCHEMBL1767983 0.90 LMNA (0.50) LMNACYP1A2CYP3A4MAOACYP2C9
Hydrochloric Acid SCHEMBL12273701 0.89 LMNA (0.49) LMNACYP1A2CYP3A4MAOACYP2C9
SCHEMBL6204523 0.87 MEN1 (0.49) CYP3A4ALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL10410232 0.86 ESR1 (0.46) LMNACYP1A2TSHRCYP2C19ALDH1A1
SCHEMBL4206097 0.84 MMP8 (0.50) CYP3A4ALDH1A1NPC1SMN1; SMN2GAA
SCHEMBL11039440 0.83 LMNA (0.53) LMNACYP1A2CYP3A4MAOACYP2C9
SCHEMBL12447998 0.83 LMNA (0.46) LMNACYP1A2CYP3A4MAOACYP2C9
SCHEMBL8029034 0.82 LMNA (0.47) LMNACYP1A2CYP3A4CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906930-B2 Quinazoline derivatives MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
US-8906930-B2 Quinazoline derivatives MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
US-8906930-B2 Quinazoline derivatives MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
EP-2504314-A1 QUINAZOLINE DERIVATIVES Merck Patent GmbH (DE) 2012-10-03 EP disclosed
US-20120238582-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-09-20 US disclosed
US-20120238582-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-09-20 US disclosed
US-20120238582-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-09-20 US disclosed
WO-2011060873-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2011-05-26 WO disclosed
WO-2011060873-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2011-05-26 WO disclosed
CN-1608061-A Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2005-04-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238582-A1 QUINAZOLINE DERIVATIVES HSP90AB1, HSP90AA1, HSP90B1 LMNA 3128/4885CYP1A2 446/4885CYP3A4 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.